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NeuroD, a transactivator of the insulin gene, is critical
for development of the endocrine pancreas, and
NeuroD mutations cause MODY6 in humans. To
investigate the role of NeuroD in differentiatedb cells,
we generated mice in which neuroD is deleted in
insulin-expressing cells. These mice exhibit severe
glucose intolerance. Islets lacking NeuroD respond
poorly to glucose and display a glucose metabolic
profile similar to immaturebcells, featuring increased
expression of glycolytic genes and LDHA, elevated
basal insulin secretion and O2 consumption, and
overexpression of NPY. Moreover, the mutant islets
appear to have defective KATP channel-mediated
insulin secretion. Unexpectedly, virtually all insulin
in the mutant mice is derived from ins2, whereas
ins1expression is almost extinguished. Overall, these
results indicate that NeuroD is required for b cell
maturation and demonstrate the importance of
NeuroD in the acquisition and maintenance of fully
functional glucose-responsive b cells.
INTRODUCTION
Diabetes is a metabolic disease that involves the death or
dysfunction of the insulin-secreting b cells of the pancreas.
Although diabetes can be managed with insulin and other drugs,
physiological glucose homeostasis is difficult to achieve by
these means, and hyperglycemia is largely responsible for the
comorbidities associated with diabetes. Consequently, much
research on diabetes is aimed at understanding the molecular
and cellular basis for pancreatic b cell development, survival,
and regulated insulin secretion in order to discover ways to
restore b cells or their functions in diabetic patients.
NeuroD is a basic helix-loop-helix (bHLH) transcription factor
that is crucial for development of the pancreas (Chae et al.,
2004; Chao et al., 2007; Huang et al., 2002; Malecki et al.,
1999; Naya et al., 1997; Naya et al., 1995). NeuroD-null mice
die of severe diabetes shortly after birth; their a and b cells are298 Cell Metabolism 11, 298–310, April 7, 2010 ª2010 Elsevier Inc.poorly differentiated, islets fail to form, and the majority of b cells
are lost (Naya et al., 1997). Although the spatiotemporal expres-
sion pattern of NeuroD during pancreatic development has been
characterized (Chae et al., 2004), its molecular, cellular, and
physiological roles are still unknown. NeuroD has been shown
to be critical for insulin gene expression in vitro (Naya et al.,
1995; Qiu et al., 2002); however, neuroD-null pancreata contain
10%–15% as much insulin as controls, an amount that has been
shown to be sufficient to support viability in mice (Bonner-Weir
et al., 1983). Therefore, the reduced amount of insulin in neu-
roD-null mice is unlikely to be the sole reason for their severe
hyperglycemia and neonatal death.
In humans, mutations in neuroD can predispose individuals to
develop maturity onset diabetes of the young (MODY6) (Malecki
et al., 1999), suggesting a critical role for NeuroD in mature
b cells. To separate out the b cell function of NeuroD, we gener-
ated mice in which neuroD is deleted in the cells that express
insulin (NeuroDloxP/; RIP:Cre mice, hereafter referred to as
neuroD b-CKO mice). In parallel, we also generated mice in
which neuroD is deleted in mature b cells in an inducible manner
(tamoxifen-injected NeuroDloxP/; Pdx1:CreERTM adult mice,
hereafter referred to as neuroD PE-CKO mice). Unlike neuroD-
null mice, neuroD b-CKO and neuroD PE-CKO mice have no
impairment of pancreatic islet formation and survive to adult-
hood. However, they are mildly hyperglycemic and contain half
the normal amount of insulin. Surprisingly, in each NeuroD
mutant model tested, almost all insulin is derived from the
expression of ins2, whereas little or no expression of ins1 is
detected. Although differential regulation of the two rodent
insulin genes has been described previously (Deltour et al.,
1993; Giddings et al., 1991; Ling et al., 1998), no transcription
factor has been linked to this phenomenon in vivo.
Although the amount of insulin found in neuroD b-CKO mice
should be sufficient to maintain normoglycemia, these mice
are severely glucose intolerant and display greatly reduced
insulin secretion. Isolated islets from neuroD b-CKO mice
respond poorly to high glucose and other fuel secretagogues
but are fully capable of insulin secretion following global
membrane depolarization with exogenous KCl. Further physio-
logical analysis of neuroD b-CKO islets suggests that they
display many characteristics of neonatal islets, which respond
poorly to glucose. For example, neuroD b-CKO islets have
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oxygen consumption, and they overexpress Neuropeptide Y,
all of which are features associated with fetal and neonatal b cells
(S. Bonner-Weir, personal communication; Asplund and Heller-
stro¨m, 1972; Boschero et al., 1990; Freinkel et al., 1984; Rozzo
et al., 2009). Deletion of NeuroD in adult b cells (neuroD PE-
CKO mice) similarly causes glucose intolerance and reversion
to immature b cell characteristics. One of the key features of
postnatal pancreatic maturation is an acquisition of glucose-
stimulated insulin secretion (GSIS), which is critical for b cell
function. The lack of this feature in neuroD b-CKO islets demon-
strates for the first time that NeuroD is essential for the mainte-
nance of b cell maturation and function, which could explain
the role of NeuroD in MODY6 (Malecki et al., 1999).
RESULTS
Impaired Glucose Tolerance and Failure to Secrete
Insulin in neuroD b-CKO Mice
To study the role of NeuroD in mature b cells, we generated
conditional knockout mice in which the RIP:Cre transgene (Her-
rera, 2000) was used to delete neuroD in 90% of differentiated
insulin-producing cells (neuroD b-CKO) (Figures S1A–S1C avail-
able online). Although NeuroD is known as a critical transcrip-
tional activator of the insulin genes (Naya et al., 1995; Qiu
et al., 2002), both male and female neuroD b-CKO mice survive
and are indistinguishable from control littermates in their appear-
ance and body weight (data not shown). In neonatal neuroD
b-CKO mice (P1.5), the blood glucose concentration was higher
and more variable than in the control mice. Periodic measure-
ments of blood glucose during maturation (1–8 weeks) and adult-
hood (10–24 weeks) showed that the mutant mice fed ad libitum
were mildly hyperglycemic (Figure 1A) with greater variability in
their blood glucose levels: 11% of readings were R 250 mg/dl
for mutant mice versus 0% for control mice (n = 148–149 per
genotype). These episodes of hyperglycemia occurred in mice
that were normoglycemic at other times, indicating that the
hyperglycemic episodes were not an inherent property of a few
individual mice.
To determine whether neuroD b-CKO mice are glucose intol-
erant, young adult mice (1–3 months) were fasted during the
day for 5 hr or overnight for 16 hr, followed by either feeding
ad libitum or intraperitoneal injection of glucose (2 g/kg body
weight). In both conditions, mutant mice had significantly higher
fasting blood glucose levels. Following feeding or glucose injec-
tion, their blood glucose rose to levels twice as high as those in
sibling control mice and took longer to return to homeostatic
levels (Figures 1B, 1C and S2A).
The glucose intolerance exhibited by the neuroD b-CKO mice
is in sharp contrast to the phenotype of neuroD-null mice, which
die shortly after birth with severe and sustained hyperglycemia
(>500 mg/dl). This difference indicates that NeuroD has a distinct
function in committed b cells that is different from its earlier
developmental function. To confirm that the phenotype of neu-
roD b-CKO mice is independent of a developmental defect, we
generated tamoxifen-inducible mice by crossing neuroDloxP/loxP
mice with Pdx:CreERTM; neuroD+/ mice that express the induc-
ible Cre recombinase (CreERTM) under the control of the Pdx-1
promoter (Gu et al., 2002). Injection of tamoxifen in adult miceC(neuroDloxP; Pdx-1:CreERTM) resulted in a 94% reduction in
neuroD mRNA in fully developed b cells, and these mice (neuroD
PE-CKO) were glucose intolerant by 3 weeks after treatment
(Figure 1D). These results indicate that glucose intolerance is
a characteristic of mice that lack NeuroD in their b cells, regard-
less of their age at the time of deletion of neuroD.
Glucose intolerance can occur because of a lack of glucose-
stimulated insulin secretion (GSIS), decreased action of insulin
in the peripheral tissues, or both. To distinguish between these
possibilities, we measured plasma insulin in neuroD b-CKO
and control mice (Figure 1E). In fasted animals, the plasma
insulin level in control mice ranged between 0.29 and 0.63 ng/ml,
whereas that of neuroD b-CKO mice was significantly lower at
0.18–0.32 ng/ml (p < 0.001). Although mean plasma insulin
was not significantly different in control and mutant mice fed
ad libitum, it ranged from 0.47 to 2.64 ng/ml in controls, whereas
it never exceeded 1.20 ng/ml in neuroD b-CKO mice. More
dramatic differences were observed following intraperitoneal
glucose injection, as the neuroD b-CKO mice were poor at
mounting an insulin secretion response when challenged with
glucose (Figure 1F). Both the first- and second-phase responses
were smaller and developed more slowly in the mutant mice.
Thus, neuroD b-CKO mice are severely deficient in GSIS, result-
ing in glucose intolerance.
Mice were also tested for their ability to take up glucose in
their peripheral tissues in response to exogenous insulin.
Although the mutant mice had a higher fasting level of blood
glucose, their ability to take up glucose was not significantly
different from controls (Figure S2B). This result indicates that
neuroD b-CKO mice are not insulin resistant, further supporting
the hypothesis that they are glucose intolerant owing to defective
insulin secretion.
Because glucose homeostasis partly depends on the balance
of glucose storage and release, we investigated whether aber-
rant levels of glucagon or perturbation of hepatic gluconeogen-
esis contributed to the phenotype of neuroD b-CKO mice.
Plasma glucagon levels were not significantly different in neuroD
b-CKO mice versus control mice regardless of whether they
were fed ad libitum, fasted for 5 hr, or fasted overnight for
16 hr (Figure 1G). These results imply that aberrations in
glucagon secretion do not account for the modest hypergly-
cemia of neuroD b-CKO mice. We also investigated whether
the mice differed in their regulation of hepatic glucose-6-phos-
phatase (G6Pase), an indicator of gluconeogenesis. Mutant
and control mice had a similar amount of hepatic G6Pase
mRNA when fasted overnight, suggesting that gluconeogenesis
was equally stimulated in both cases (Figure 1H). However, at
90 min after glucose injection, G6Pase mRNA fails to decrease
in the mutant mice. Because insulin is a powerful inhibitor of
G6Pase expression (Onuma et al., 2009), the failure to downre-
gulate G6Pase mRNA in neuroD b-CKO mice is likely due to their
severe insulin secretion defect. Therefore, in neuroD b-CKO
mice, sustained gluconeogenesis may exacerbate hypergly-
cemia during glucose challenge.
Islet Morphology and b Cell Phenotype
in the neuroD b-CKO Pancreas
Because neuroD-null mice fail to form mature islets (Naya et al.,
1997), we investigated whether neuroD b-CKO mice are glucoseell Metabolism 11, 298–310, April 7, 2010 ª2010 Elsevier Inc. 299
Figure 1. Physiological Effects of b Cell-Specific Ablation of neuroD
(A) Blood glucose levels of neuroD b-CKO and control mice fed ad libitum: P1.5 (n = 9–21), 1–8 weeks (n = 114–115), and 10–24 weeks (n = 34–35).
(B) Blood glucose levels of neuroD b-CKO and control mice fasted for 16 hr and fed mouse chow (n = 9 per genotype).
(C) Glucose tolerance test for neuroD b-CKO and control mice (n = 10–11 per genotype).
(D) Glucose tolerance test for neuroDloxP/; PE-Cre and neuroDloxP/+; PE-Cre pre-tamoxifen injection and post-tamoxifen injection (n = 8–9 each type).
The neuroDloxP/ ; PE-Cre mice with tamoxifen injection are considered as neuroD PE-CKO.
(E) Plasma insulin levels after fasting (16 hr) or fed ad libitum (n = 9–16 per genotype).
(F) Plasma insulin levels after glucose injection (n = 5–7 per genotype).
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Figure 2. Effect of b Cell-Specific Ablation
of neuroD on Islet Characteristics
(A–H) Pancreatic sections from control, neuroD
b-CKO, and neuroD PE-CKO mice were immuno-
stained for insulin (green) and for either glucagon
(red, A–D) or somatostatin (red, E–H). Nuclei are
stained with DAPI (blue). The white arrows in (F)
and (H) indicate insulin and somatostatin cos-
tained cells. Original magnification was 2003.
(I–L) The expression of Glut-2 (red) in the control,
neuroD b-CKO, and neuroD PE-CKO pancreas.
Original magnification was 2003.
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Pancreata from perinatal and 7-week-old mice were stained
with antibodies to glucagon, insulin, somatostatin, and pancre-
atic polypeptide as markers for a, b, d, and PP cells, respectively.
Although neuroD b-CKO mice formed islets similar in size to
those of control mice, their a, d, and PP cells were intermingled
in the b cell core instead of residing at the periphery (Figures 2A,
2B, 2E, 2F, S3A, S3B, S5A, and S5B; data not shown). Of
interest, the neuroD PE-CKO mice did not display disrupted islet
architecture, suggesting that this phenotype is associated with
a developmental defect (Figures 2C, 2D, S5C, S5D). The number
of cells costained for insulin and somatostatin was increased in
both the neuroD b-CKO and neuroD PE-CKO mice. The cells co-
expressing insulin and somatostatin were elevated 60-fold in the(G) Plasma glucagon levels fed ad libitum, fasted for 5 hr, or fasted for 16 hr) (n = 10–17 per genotype).
(H) The expression of G6Pase in control and neuroD b-CKO after fasted for 16 hr (0) and 90 min after
b2-microglobin mRNA and expressed as relative to control (n = 5 per genotype).
*p% 0.05; **p% 0.01; and ***p% 0.001. Results are expressed as mean ± SEM.
Cell Metabolism 11, 298–islets of neuroD b-CKO mice: 0.77% of
insulin-positive cells coexpressed so-
matostatin versus 0.013% in controls
(Figures 2E–2H). However, the total
number of cells involved is small and
thus may not contribute to the overall
physiology of neuroD b-CKO mice. Islet
amyloid polypeptide (IAPP), another
b cell marker, is not significantly different
in neuroD b-CKO and control mice, indi-
cating that other b cell characteristics
are intact in the mutant b cells (Figures
S3C and S3D). To determine whether
the failure to respond to glucose occurs
at the level of glucose transport across
the membrane, we examined the level of
Glut-2 in neuroD b-CKO mice and found
that the mutant b cells have only half as
much Glut-2 protein as controls, as deter-
mined by quantification of immunostain-
ing (Figures 2I and 2J). However, neuroD
PE-CKO mice, which are also glucose
intolerant, have normal amounts of
Glut2 in their islets at both 3 weeks and
2 months after tamoxifen treatment was
initiated (Figures 2K, 2L, S5E, and S5F),indicating that reduction of Glut-2 is not responsible for glucose
intolerance observed in both strains. Importantly, Pdx-1, Nkx6.1,
and MafA, all of which are b cell transcription factors that are
involved in the activation of insulin transcription and the regula-
tion of insulin secretion (Ohlsson et al., 1993; Schisler et al.,
2005; Wang et al., 2007), are unaffected by the absence of Neu-
roD (Figures S3E–S3J and S3K). These results indicate that the
defective GSIS observed in neuroD b-CKO mice is not
a secondary consequence of altered regulation of these tran-
scription factors.
Because apoptosis is increased 10-fold in neuroD-null mice
(Naya et al., 1997), we investigated whether apoptosis is also
increased in neuroD b-CKO mice. We measured apoptosis by
immunostaining for activated caspase 3 and also examinedglucose injection (90). Values were normalized to
310, April 7, 2010 ª2010 Elsevier Inc. 301
Figure 3. Deletion of neuroD Results in Loss of Insulin 1
(A–H) Pancreatic sections from control, neuroD b-CKO, and neuroD PE-CKO
mice were costained with antibodies to insulin (green) and C-peptide 1 (red)
(A and B, E and F) or C-peptide 2 (C and D, G and H).
(I) Quantitative RT-PCR of ins1 and ins2 mRNA levels in control, neuroD
b-CKO, and neuroD PE-CKO islets. Values were normalized to b-actin
Cell Metabolism
Role of NeuroD in Mature Pancreatic b Cells
302 Cell Metabolism 11, 298–310, April 7, 2010 ª2010 Elsevier Inc.compensatory b cell proliferation by immunostaining for PCNA
and Ki67. Overall, only a small fraction of the b cells were
engaged in either proliferation (%2%) or apoptosis (%2%) in
neuroD b-CKO and control islets, indicating that deletion of
NeuroD in differentiated b cells does not cause increased
apoptosis or proliferation, which is consistent with the observed
normal islet area in these mice.
Expression of Insulin 2, but Not Insulin 1,
in neuroD b-CKO Mice
Detection of a significant amount of insulin staining in the b cells
of neuroD b-CKO islets was surprising because previous studies
had shown that NeuroD is a critical factor for insulin gene
transcription (Naya et al., 1995; Qiu et al., 2002). Morphometric
quantification of > 500 islets indicated that, on average, the
intensity of insulin staining in neuroD b-CKO islets was half that
of control islets. Moreover, although we observed no significant
difference in either islet size or islet number between control and
neuroD b-CKO mice, neuroD b-CKO pancreata contain 53% as
much insulin as control pancreata (15.3 ± 4.2 ug/mg versus
29.0 ± 7.8 ug/mg protein, n = 7–13, p < 0.001). Taken together,
these data indicate that neuroD b-CKO islets contain half the
normal amount of insulin due to a corresponding reduction in
insulin content per cell rather than a reduction in cell number.
Because rodents express two closely related insulin genes,
ins1 and ins2 (Davies et al., 1994), we measured the level of
expression of each insulin gene to determine the source of the
remaining insulin in neuroD b-CKO mice. In pancreatic sections
costained for insulin and C-peptide 1, > 90% of the b cells in
neuroD b-CKO pancreata lacked C-peptide 1 staining, suggest-
ing that they fail to express ins1. In striking contrast, C-peptide 2
was present in all of the mutant b cells, implying that ins2 expres-
sion is relatively unaffected (Figures 3A–3D). Consistently, ins1
transcripts are also reduced by 95% in neuroD b-CKO islets,
whereas ins2 transcripts are present at a level comparable to
controls (Figure 3I). These data indicate that neuroD is not
required for ins2 expression in vivo but is necessary for ins1
expression. Deletion of neuroD in adult b cells using the neuroD
PE-CKO mice also resulted in the loss of ins1, but not ins2,
expression (Figures 3E–3I). The differential regulation of ins1
and ins2 does not appear to be an artifact associated with the
neuroD conditional allele because we also detect a dramatic
decrease in immunostaining for C-peptide 1, but not C-peptide
2, in the few remaining b cells in e18.5 neuroD-null pancreata
(Figure S4A–S4D). Furthermore, in the neuroD-null embryos,
there is a gradual decline in the ratio of ins1/ins2 mRNA between
e14.5 and P0 (Figure S4E). A similar phenomenon can be
observed in the postnatal neuroD b-CKO mice, in which the
ratio of ins1/ins2 mRNA declines from 80% of control at e18.5
to < 10% of control at 2 months (Figure S4F).
Previous studies have shown that mice can lack either one of
the insulin genes and remain glucose tolerant (Leroux et al.,
2001). We confirmed this result independently in ins1 null mice
(data not shown). Moreover, studies of pancreatectomized ani-
mals have indicated that half the normal amount of insulin is more
than sufficient to maintain glucose homeostasis (Bonner-WeirmRNA and expressed as relative to the respective controls (n = 4–6 per
genotype). ***p% 0.001. Results are expressed as mean ± SEM.
Figure 4. Insulin Secretion Profiles in neuroD b-CKO Islets
(A) Isolated islets from control and neuroD b-CKO mice treated with different insulin secretagogues (2.8 mM glucose, 16.7 mM glucose, 20 mM leucine, 30 mM
KCl, 50 uM glipizide, and 10 mM methyl pyruvate). Secreted insulin was normalized to total insulin in the islets (n = 6–10 per genotype).
(B) Quantitative RT-PCR of Kir6.2, Sur1, piccolo, and Noc2 mRNA in control and neuroD b-CKO islets. The data were normalized to b-actin mRNA
(n = 3–8 per genotype).
(C) Respiration rate of control and neuroD b-CKO islets incubated with glucose and oligomycin (OM) (n = 6–17 per genotype).
*p% 0.05; **p% 0.01; and ***p% 0.001. Results are expressed as mean ± SEM.
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reduction in total insulin, accounts for the defective insulin secre-
tion and glucose intolerance of neuroD b-CKO mice.
Formation of Dense Core Granules in neuroD
b-CKO Mice
Insulin secretion is poor in some diabetic mouse models
because of a paucity of insulin dense core granules (DCGs) in
the b cells (Bruin et al., 2008; Like and Rossini, 1976; Pechhold
et al., 2009; Piaggi et al., 2007). In addition, fewer DCGs are
present in the underdeveloped b cells of neuroD-null mice
(data not shown). We analyzed b cells of neuroD b-CKO mice
using electron microscopy to determine whether they have
normal DCGs. The mutant b cells contain a large number of
DCGs, similar to those of control mice, implying that neitherCdefective formation of DCGs nor depletion thereof is the reason
for defective insulin secretion in neuroD b-CKO mice (Figures
S4H and S4I).
Defects in Stimulus-Secretion Coupling in Isolated
Islets from neuroD b-CKO Mice
To understand the physiological basis of defective GSIS
observed in the NeuroD mutant mice, we stimulated islets
isolated from control and neuroD b-CKO mice with a variety of
insulin secretagogues (Figure 4A). The amount of secreted
insulin was normalized to total insulin content to take into
account the reduction of insulin in the neuroD b-CKO islets.
We found that the mutant islets secrete a larger percentage of
their insulin (0.13 ± 0.01% versus 0.05 ± 0.01% for controls)
under basal conditions (2.8 mM glucose). However, during 1 hrell Metabolism 11, 298–310, April 7, 2010 ª2010 Elsevier Inc. 303
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secreted 1.0% of their insulin, whereas the neuroD b-CKO islets
secreted only 0.26% of their insulin (Figure 4A). The mutant islets
also responded poorly to leucine (Figure 4A). These secretion
defects do not appear to be associated with a lack of readily
releasable insulin granules because exposure of neuroD b-
CKO islets to 30 mM KCl induced robust insulin secretion that
was not significantly different from control islets (Figure 4A).
Extensive in vitro and in vivo studies of the gene products
associated with MODY have suggested that they play a predom-
inant role in glucose-sensing insulin secretion coupling (Giuffrida
and Reis, 2005; Mitchell and Frayling, 2002). Because Sur1, a
regulatory subunit of the pancreatic KATP channel, has been
shown to be a transcriptional target of NeuroD in vitro (Keller
et al., 2007; Kim et al., 2002), we assessed whether neuroD
b-CKO mice display defective KATP channel function. Consistent
with a defect in KATP channel function, neuroD b-CKO islets
respond poorly to glipizide, a sulfonylurea drug, by secreting
only 0.22% of their insulin content versus 0.79% for control islets
(Figure 4A). Of interest, there is no difference in the mRNA
expression of the KATP channel gene (Kir6.2, kcnj11) or its regu-
latory subunit (Sur1, abcc8) between mutant and control islets
(Figure 4B), indicating that NeuroD does not regulate these
genes at the level of transcription in vivo.
It remains possible that NeuroD affects other aspects of KATP
channel activity. The neuroD b-CKO islets respond poorly to
methyl pyruvate (Figure 4A) and are deficient in molecules that
link the activity of KATP channels to other parts of the machinery
necessary for regulated insulin exocytosis. The expression of
Piccolo (pclo) and Noc2 (rph3al) are both decreased in the neu-
roD b-CKO islets (Figure 4B). Pclo encodes a scaffold protein
that is necessary for assembly of insulin secretion complexes
that link KATP channels, L-type calcium channels, and insulin
granules into functional units (Shibasaki et al., 2004), and Noc2
is a Rab effector that is required for GSIS through its interaction
with small monomeric GTPases (Cheviet et al., 2004).
We also investigated whether there are defects in the steps
that precede closure of the KATP channel in neuroD b-CKO islets.
We measured O2 consumption in islets cultured in low and high
glucose to measure the degree of oxidative metabolism that
leads to ATP production. Compared to the controls, the mutant
islets had a significantly greater rate of O2 consumption under
the basal conditions (Figure 4C). When challenged with high
glucose, O2 consumption increased to a lesser extent in mutant
than control islets but achieved a similar rate overall. Virtually all
of the O2 consumption in mutant and control islets was inhibited
by treatment with the ATP synthase inhibitor Oligomycin A,
implying that it is coupled to ATP production (Figure 4C). Of
interest, these characteristics of respiration in neuroD b-CKO
islets resemble those of GSIS-deficient neonatal islets (Boschero
et al., 1990).
Defects in the Amplification of GSIS in neuroD
b-CKO Islets
Although global membrane depolarization by KCl releases a
normal amount of insulin from neuroD b-CKO islets, their
reduced secretion of insulin in response to glucose, other fuel
secretagogues, and glipizide implies that they are defective in
the initial phase of GSIS upstream of Ca2+ influx. Therefore, to304 Cell Metabolism 11, 298–310, April 7, 2010 ª2010 Elsevier Inc.determine whether the mutant islets are capable of amplifying
their insulin secretion following Ca2+ influx, we treated them
with BayK8644, a drug that specifically opens L-type voltage-
sensitive calcium channels (VDCCs), together with 16.7 mM
glucose. The mutant islets secreted 2.6% of their total insulin,
which is 10 times greater than their response to high glucose
alone but is still less than the 4.7% of insulin secreted by the
control islets (Figure 5A). Similar results were obtained using
20 mM L-arginine to enhance plasma membrane depolarization
in the mutant and control islets. In addition, an agent (cAMP) that
enhances the amplifying phase of GSIS (Doyle and Egan, 2003)
also partially rescued insulin secretion in the mutant islets
(Figure 5A). Thus, neither type of treatment alone fully rescued
insulin secretion in neuroD b-CKO islets, suggesting that the
mutant islets have defects in both the initial and amplifying
phases of GSIS.
Adenyl cyclase activity, which is necessary for the conversion
of ATP to cAMP, is inhibited by Neuropeptide Y (NPY), a hormone
whose expression is normally decreased in islets after birth
(Figures S6A–S6J) (Motulsky and Michel, 1988). We found that
NPY mRNA is significantly increased in the neuroD b-CKO and
neuroD PE-CKO islets and that the immunostaining of NPY is
clearly increased in > 40% of the mutant b cells of each strain
(Figures 5B–5J). The upregulation of NPY in the b cells of neuroD
b-CKO and neuroD PE-CKO mice may contribute to their
observed GSIS defects by decreasing the level of cAMP.
Increased Glycolytic Gene Expression
in the neuroD b-CKO Islets
Impaired GSIS, as well as elevated rates of O2 consumption and
insulin secretion in basal conditions, are properties shared by
neuroD b-CKO islets and fetal b cells (Freinkel et al., 1984;
Hughes, 1994; Rozzo et al., 2009; Tu and Tuch, 1996). To inves-
tigate whether neuroD b-CKO islets display an expression profile
similar to functionally immature b cells, we performed unbiased
global gene expression analyses of adult islets isolated from pan-
creata of the neuroD b-CKO mice and their littermate controls.
Sixty-eight genes were significantly affected by the deletion of
neuroD in b cells (Tables S1 and S2). These results indicated
that expression of lactate dehydrogenase A (LDHA) was signifi-
cantly altered in the adult neuroD b-CKO islets. Normally, mature
b cells are different than most mammalian cell types in that
they have an unusually low amount of lactate dehydrogenase
(LDH) (Schuit et al., 1997; Sekine et al., 1994). In contrast, fetal
and neonatal b cells have elevated amounts of LDHA and an
increased rate of glycolysis (Figure S6L) (S. Bonner-Weir,
personal communication; Boschero et al., 1990). Surprisingly,
LDHA (ldha) mRNA and protein are increased dramatically in
neuroD b-CKO islets in both low glucose and high glucose
(Figures 6A–6E and 6J). Accordingly, the mutant islets exhibit
a 3.5-fold increase in LDHA activity, a 2-fold increase in lactate
production, and a > 2-fold increase in LDHA immunostaining
(Figures 6K and 6L). Furthermore, neuroD b-CKO islets have
elevated expression of several other glycolytic genes, including
aldolase B, phosphofructokinase, liver form (PFKL), triose phos-
phate isomerase (TPI), enolase 1 (ENO1) and pyruvate kinase,
liver, and RBC form (PKLR) (Figure 6A). These changes in gene
expression suggest that glycolysis is enhanced in neuroD
b-CKO islets. In contrast, there is no significant difference in the
Figure 5. Deletion of neuroD Leads to Increased
NPY Expression
(A) Isolated islets from control and neuroD b-CKO mice
treated with different insulin secretagogues (2 uM
BayK8644, 20 mM L-arginine, and 1 mM dibutyryl cAMP)
in the presence of 16.7 mM glucose. Secreted insulin
was normalized to total insulin in the islets (n = 6–9 per
genotype).
(B) Quantitative RT-PCR of NPY mRNA in control, neuroD
b-CKO, and neuroD PE-CKO islets. The data were normal-
ized to b-actin mRNA (n = 4–8 per genotype) and pre-
sented as relative to the respective controls.
(C–J) Coimmunostaining of neuropeptide Y (red) and
insulin (green) in the pancreatic sections of control for
neuroD b-CKO (C and D), neuroD b-CKO (E and F), control
for neuroD PE-CKO (G and H), and neuroD PE-CKO (I and
J). Nuclei are stained with DAPI (blue). Original magnifica-
tion was 2003.
*p% 0.05; **p % 0.01; and ***p% 0.001. Results are ex-
pressed as mean ± SEM.
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metabolism and oxidative phosphorylation in mitochondria, such
as pyruvate dehydrogenase A1 (Pdha-1) and its regulatory protein
pyruvate dehydrogenase kinase 1 (PDK1), succinate dehydroge-
nase C (SDHC), and ATP synthase (ATP6) (Figure 6A). Overall,
the pattern of gene expression in neuroD b-CKO islets is consis-
tent with the increase in glycolysis that is characteristic of neonatal
b cells (Boschero et al., 1990). Comparable increases in LDHACell Metabolism 1mRNA and immunostaining, and glycolytic gene
expression, also occur in neuroD PE-CKO islets,
indicating that adult b cells require NeuroD to
maintain their mature metabolic phenotype
(Figures 6A and 6F–6I).
DISCUSSION
NeuroD is known to be important for b cell
development and insulin transcription; however,
which aspects of b cell development and mature
b cell function require NeuroD is not clearly
understood. To determine the specific role of
NeuroD in mature b cells, we generated neuroD
b-CKO mice, in which NeuroD is deleted in the
insulin-producing cell population at the onset
of their formation. These mice survive and
form islets that contain half the normal amount
of insulin, and yet they are severely glucose
intolerant. To determine whether continued
function of NeuroD is required in mature adult
b cells, we also deleted neuroD de novo in adult
mice (neuroD PE-CKO) using inducible expres-
sion of Cre recombinase and found that these
mice largely phenocopy the neuroD b-CKO
mice. We performed extensive molecular,
cellular, and physiological analyses on both
mouse models and found that: (1) despite the
widely accepted belief that NeuroD is a critical
transcription factor for insulin gene transcrip-tion, NeuroD is dispensable for ins2 gene expression in mice;
(2) although b cells lacking NeuroD produce sufficient insulin to
support glucose homeostasis, the mutant mice are glucose intol-
erant, indicating that NeuroD regulates other aspects of b cell
function that are unrelated to insulin transcription; (3) continued
activity of NeuroD is required for the proper function of b cells,
providing the molecular and physiological basis for MODY6;
and (4) b cells lacking NeuroD have a striking resemblance to1, 298–310, April 7, 2010 ª2010 Elsevier Inc. 305
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Role of NeuroD in Mature Pancreatic b Cellsimmature b cells, indicating that NeuroD plays an important role
in achieving and maintaining maturity of b cells.
NeuroD and Activation of Insulin Transcription
NeuroD b-CKO mice retain half the normal amount of insulin
because activation of the ins2 gene is unaffected in vivo both
during development and in adult mice. Although differential
expression of ins1 and ins2 has been detected under certain
physiological conditions (Deltour et al., 1993; Giddings et al.,
1991; Ling et al., 1998), this is the first time that a transcription
factor has been associated with their differential regulation
in vivo. This result was surprising because several prior in vitro
studies have shown that NeuroD is capable of activating both
ins1 and ins2 through conserved E box elements (Clark and
Docherty, 1993; German et al., 1991; Naya et al., 1995). There-
fore, it was anticipated that expression of both genes would be
affected in the absence of NeuroD. On the other hand, each of
the E box elements in the rat and human insulin genes has
been shown to contribute variably to the regulation of ins expres-
sion (Crowe and Tsai, 1989; Karlsson et al., 1987). Our results
demonstrate that such differential regulation of two rodent ins
genes is mediated through NeuroD and that NeuroD is dispens-
able for ins2 gene expression in its native in vivo environment.
To resolve the divergent mechanisms by which the insulin genes
are regulated, it will be necessary to perform complementary
in vitro and in vivo studies to understand fully the direct regula-
tion of ins1 and ins2 by NeuroD and perhaps other E box-binding
factors.
Mild Hyperglycemia and Severe Glucose Intolerance
Because neuroD b-CKO mice exhibit severe glucose intoler-
ance, it seems paradoxical that they are only mildly hypergly-
cemic when fed ad libitum. It is unlikely that induced changes
in hepatic glucose output can explain this phenotype because
neuroD b-CKO mice fasted for 5 hr or 16 hr have similar amounts
of plasma glucagon compared to control mice. It is also possible
that insulin secretion is increased under ad libitum feeding condi-
tions owing to mechanisms that do not depend on GSIS. The
Sur1 knockout mice are also glucose intolerant and yet normo-
glycemic when fed ad libitum (Seghers et al., 2000), and it is
believed that they secrete nearly normal amounts of insulin in
response to feeding due to cholinergic stimulation of insulin
secretion (Shiota et al., 2002). Similar compensatory mecha-
nisms may regulate glucose homeostasis in neuroD b-CKO
mice fed ad libitum.
NeuroD Regulates b Cell Maturation
Isolated islets from neuroD b-CKO mice have a metabolic profile
that resembles that of immature pancreatic b cells, which are
found in late fetal or neonatal islets. Both the mutant b cells
and immature b cells have insulin secretory granules but lackFigure 6. Increased Expression of Glycolytic Genes
(A) Quantitative RT-PCR of genes involved in glycolysis and mitochondrial functi
(B–I) Coimmunostaining of LDHA (red) and insulin (green) in the pancreatic sectio
mice (H and I). Nuclei are stained with DAPI (blue). Original magnification was 20
(J) Increased LDHA protein in both low glucose (2.8 mM) and high glucose (16.7
(K and L) Increased LDHA activity and increased production of lactate in neuroD
*p% 0.05; **p% 0.01; and ***p% 0.001. Results are expressed as mean ± SEM
CGSIS. Compared to mature b cells, immature b cells have a
higher rate of O2 consumption, produce more lactate, and
secrete more insulin under basal conditions (Boschero et al.,
1990; Rozzo et al., 2009), and these properties also characterize
neuroD b-CKO islets. When challenged with high glucose, imma-
ture b cells fail to increase their oxidative metabolism as dramat-
ically as do mature b cells and consequently fail to secrete as
much insulin (Hughes, 1994; Rozzo et al., 2009; Tu and Tuch,
1996). Glycolysis predominates in fetal and neonatal islets,
resulting in impaired GSIS, which relies on oxidative metabolism
of glucose. Likewise, we found that expression of a number of
glycolytic genes, including lactate dehydrogenase A (LDHA),
was increased in neuroD b-CKO and neuroD PE-CKO islets.
LDHA is of particular importance because it converts pyruvate
to lactate in the cytosol, thereby preventing its oxidative metab-
olism in mitochondria. LDHA is expressed at high levels in the
embryonic and neonatal pancreas but becomes downregulated
in the adult islets (Figure S6L). Accordingly, the reduction of
LDHA in mature b cells is believed to be critical for their ability
to couple glucose metabolism to insulin secretion (Schuit et al.,
1997; Sekine et al., 1994; Zehetner et al., 2008; Zhao and Rutter,
1998). Thus, it is likely that NeuroD plays a major role in b cell
maturation by downregulating LDHA and other glycolytic genes
because these changes are necessary for efficient oxidative
metabolism of glucose and GSIS in mature b cells. Of interest,
mice with a b cell-specific knockout of the von Hippel-Lindau
gene (vhlh) also displayed increased insulin secretion in low
glucose and decreased GSIS owing to overexpression of
LDHA and other glycolytic genes (Zehetner et al., 2008). The
phenotype of the vhlh-deficient islets results from activation of
Hif1a (Zehetner et al., 2008); however, it is unlikely that this
pathway is operating in neuroD b-CKO islets because other
genes that are strongly upregulated by Hif1a, including vegfa
and pdk1, are unaffected in neuroD b-CKO islets (data not
shown). Currently, we do not have evidence that LDHA or the
glycolytic genes that we examined are direct targets for NeuroD
(Keller et al., 2007). There is a canonical NeuroD E box (CATCTG)
at position 430 in the LDHA promoter of mice and rats, but this
site is not conserved in the human gene.
NeuroD b-CKO mice have defects in the mechanism for GSIS
beyond their immature oxidative metabolism of glucose. In
particular, neuroD b-CKO islets secrete insulin poorly in
response to glipizide-mediated closure of their KATP channels.
Physiological induction of insulin secretion by closure of KATP
channels involves the elevation of cytosolic [Ca2+] in a microenvi-
ronment around docked and primed insulin granules (Bokvist
et al., 1995). This process is facilitated by the formation of an
insulin secretion complex that links the ATP sensor (Kir6.1 and
Sur1), cAMP sensor (cAMPGEFII), VDCCs, and insulin granules
into a functional unit (Shibasaki et al., 2004). Because NeuroD-
deficient b cells have the basic components necessary for theon (n = 4–8 per genotype). {: Error bar ± 1.85; y: Error bar ± 3.78.
ns from control (B, C, F, and G), neuroD b-CKO (D and E), and neuroD PE-CKO
03.
mM) in the neuroD b-CKO islets.
b-CKO islets (n = 8–11).
.
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able insulin granules, and ATP-coupled O2 consumption, we
hypothesize that they are deficient in GSIS because they lack
the structure necessary for those components to function
together. In support of this hypothesis, we found that neuroD
b-CKO islets have decreased expression of piccolo, a large scaf-
fold protein and possible Ca2+ sensor that helps form this
complex, and Noc2, a Rab effector that is associated with the
insulin secretory granules and is required for efficient GSIS (Che-
viet et al., 2004). NeuroD may also be important for the expres-
sion of key exocytotic proteins, such as SNAP25 and syntaxin1A
(Ishizuka et al., 2007). Given the apparent immaturity of b cells
that lack NeuroD, our hypothesis suggests further that formation
of the insulin secretion complex may be a key step in b cell
maturation.
Early precursor cells in the endocrine pancreas coexpress
insulin and neuropeptide Y (NPY), but as development proceeds,
NPY is decreased in b cells (Figures S6A–S6J) (Teitelman et al.,
1993). NPY inhibits adenyl cyclase and cAMP production (Motul-
sky and Michel, 1988), which is required for efficient GSIS. The
inhibitory role of NPY in GSIS has been demonstrated in several
rodent models and in isolated islets (Imai et al., 2007; Myrse´n-
Axcrona et al., 1997; Myrse´n et al., 1995; Wang et al., 1994).
Consistent with the immature state and impaired GSIS of b cells
that lack NeuroD, NPY mRNA and protein are greatly increased
in both neuroD b-CKO and neuroD PE-CKO islets. Thus, it
appears that NeuroD plays a global role in both activating
b cell maturation-specific genes and downregulating immature
b cell-specific genes. A recent study has demonstrated that
neonatal islets display a molecular profile that is distinct from
the adult islets and identified a number of markers displaying
transient expression in the perinatal period (Aye et al., 2010). In
support of our hypothesis, the gene encoding one of the markers
of neonatal b cells, CK19, is highly upregulated in the neuroD
b-CKO islets (Figure S6M). NeuroD mRNA levels also gradually
increase during this early postnatal maturation period
(Figure S6K); however, because NeuroD activity also depends
on posttranscriptional and posttranslational regulation, we
need to further determine which of these gene expression
changes are due to direct or indirect regulation by NeuroD.Importance of NeuroD for Creation of b Cells Suitable
for Therapy
The creation of functional b cells suitable for transplantation into
patients with diabetes is a major goal of research on therapies for
diabetes. Although many studies have attempted to produce
b cells from many different cell sources, they have only been
partially successful in inducing b cell differentiation (D’Amour
et al., 2006; Jiang et al., 2007). Meanwhile, generation of mature
b cells with tight control of insulin secretion in low glucose and
a robust GSIS response in high glucose in vitro has not been
successful. Our study of neuroD b-CKO and neuroD PE-CKO
mice has shown that NeuroD is required for the transition of
b cells from an immature to mature state during development
and that NeuroD is essential for the maintenance of the mature
b cell state in the adult. Thus, understanding the role of NeuroD
in promoting b cell maturation could help point the way toward
achieving b cell maturation in vitro.308 Cell Metabolism 11, 298–310, April 7, 2010 ª2010 Elsevier Inc.EXPERIMENTAL PROCEDURES
Immunostaining and Morphometric Analysis of Islets
Pancreata were fixed with 4% paraformaldehyde, cryosectioned, postfixed in
methanol:acetone (1:1) for 5 min at 20C, and stained with the primary and
secondary antibodies listed in Table S3. Antigen retrieval was used prior to
staining for nuclear factors. Morphometric analysis was carried out using
Slidebook 4.1 software (Intelligent Imaging Innovations) to quantify the area,
intensity, and overlap of staining for each antigen. The fraction of NPY-positive
b cells was confirmed by counting immunostained cells in three islets of each
genotype.
LDH Activity and Lactate Assay
LDH activity was measured with an LDH assay kit (Cayman), and lactate
production was analyzed with a lactate assay kit (Biovision). Additional details
are provided in Supplemental Information.
Measurement of O2 Consumption
O2 consumption was measured using a 96-well BD Oxygen Biosensor plate
(BD). Equilibrated islets were added to the BD Oxygen Biosensor plate
at 50 islets/well, and O2 consumption was measured at 1 min intervals in a
fluorometric plate reader (Bio-Tek) at 37C. DNA content of the islets was
determined with Picogreen dye (Invitrogen).
Insulin Secretion Assay
Equilibrated islets were placed in wells of a 24-well plate at 10–15 islets/well
with 400 ul Kreb’s buffer containing 2.8 mM glucose and incubated for 1 hr,
and the supernatant was collected to measure basal insulin secretion. The
islets were transferred to Kreb’s buffer containing different insulin secreta-
gogues (see Results) and incubated for 1 hr before the supernatant was
collected. The islets were sonicated in 500 ul lysis buffer (10 mM Tris
[pH 7.5], 200 mM NaCl and 1 mM EDTA), and insulin was extracted by acid
ethanol. Insulin in supernatants and islet lysates was measured with a rat
insulin RIA kit (Millipore). Methyl pyruvate, dibutyryl cAMP, and Bay K8644
were purchased from Sigma.
Microarray
Total RNA was extracted from adult islets, and islet purity was assessed and
matched for four pairs of control and mutant RNA samples. 25 ng of each
RNA sample was amplified using the Ovation RNA Amplification system V2
(Nugen, Inc.). The mouse PancChip 6.0 was used for microarray analysis
(Kaestner et al., 2003). Genes that exhibited a fold change > 1.5, with
a FDR% 5%, are shown in Tables S1 and S2.
Statistics
Results are expressed as means ± SEM, and significance was determined by
Student’s t test for two-tailed unpaired groups. p % 0.05 was considered
significant.
ACCESSION NUMBERS
The NeuroD islet microarray expression data sets have been deposited at
ArrayExpress (http://www.ebi.ac.uk/microarray-as/ae/) under experiment
accession number E-MTAB-152.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and five tables and can be found with this article online at
doi:10.1016/j.cmet.2010.03.006.
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